SpeeDx Increase Distribution Network
18.3.2021 10:00:00 EET | Business Wire | Press release
SpeeDx have announced signing a new distribution partner, further extending customer access to market-leading SpeeDx Resistance Plus® and Plex PCR® tests. Neogen Diagnostik Sağlık Hizmetleri Ltd Şti will distribute all SpeeDx tests throughout Turkey.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210318005254/en/
“Neogen Diagnostik are a great fit for SpeeDx products and we are looking forward to working with them to give Turkish laboratories the opportunity to provide ResistancePlus tests and support the use of Resistance Guided Therapy with their clinician partners.” - Warwick Need, SpeeDx Director of Sales (Graphic: Business Wire)
“We continue to see demand for our key tests and technology around the world,” says Warwick Need, SpeeDx Director of Sales. “Neogen Diagnostik are a great fit for SpeeDx products and we are looking forward to working with them to give Turkish laboratories the opportunity to provide ResistancePlus tests and support the use of Resistance Guided Therapy with their clinician partners.”
In addition to Resistance Plus GC* - combining Neisseria gonorrhoeae (GC) detection with markers for ciprofloxacin susceptibility, and Resistance Plus MG* - simultaneously detecting Mycoplasma genitalium and genetic markers for azithromycin resistance, the SpeeDx sexual health portfolio includes Plex PCR VHS* - a multiplex test for herpes simplex virus (1 and 2), varicella zoster and Treponema pallidum (syphilis), and Plex PCR HSV-1&2, VZV.
SpeeDx are also growing their Respiratory portfolio with the recently launched Plex PCR RespiVirus - a comprehensive multiplex panel for respiratory virus testing, and the soon to be launched Plex PCR SARS-CoV-2 test – a dual target COVID-19 assay for confident detection of all currently known circulating variants. A respiratory bacterial infection testing solution will also be launched this year.
“Neogen Diagnostik is pleased to make Resistance Guided Therapy available to all stakeholders in the Turkey healthcare chain from clinicians and lab specialists to patients through this distributorship deal with SpeeDx. This is absolutely of medical value complementing the rational use of antibiotics when treating patients. SpeeDx solutions will be a real diagnostic tool for clinicians when deciding on the best possible treatment options for their patients,” Abdulmecit Arikan, founder of Neogen Diagnostik, said in a statement.
*available where CE-mark is accepted, not available in the U.S.
About SpeeDx Pty Ltd
Founded in 2009, SpeeDx is an Australian-based private company with offices in London and the US, and distributors across Europe. SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management. Innovative real-time polymerase chain reaction (qPCR) technology has driven market-leading multiplex detection and priming strategies. SpeeDx has a portfolio of CE-IVD kits for detection of infectious disease pathogens, sexually transmitted infection (STI), and antimicrobial resistance markers. SpeeDx Resistance Plus tests enable Resistance Guided Therapy, improving patient outcomes by empowering practitioners to make informed clinical decisions.
For more information about SpeeDx please see: http://plexpcr.com
About Neogen Diagnostik Sağlık Hizmetleri Ltd Şti
Neogen Diagnostik is a medical company founded by Abdulmecit Arikan, a Molecular Biologist with 18 years of experience in executive positions at a leading multinational diagnostics company and 20+ years corporate experience. Neogen Diagnostik is committed to providing access to advanced technologies used for diagnostic purposes in healthcare, believing that innovative technologies with value-based solutions can eliminate the existing obstacles in molecular diagnostics.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210318005254/en/
Contact information
Madeline O’Donoghue
Global Marketing Director
madelineo@speedx.com.au
+61 2 9209 4170
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New AI Research from GFT Technologies: 84% of CIOs Have Canceled an AI Project Over Legacy System Limits29.9.2026 15:07:00 EEST | Press release
A new AI study from GFT Technologies, an AI-centric global digital transformation company, finds that legacy infrastructure is one of the biggest obstacles to enterprise AI success, with the vast majority of technology leaders reporting it has forced them to abandon AI initiatives. The GFT survey, conducted by Wakefield Research among 945 CIOs and CTOs across 19 countries at companies with at least $500M in annual revenue (fielded August 11-31, 2026), reveals that AI's promise and its risks are accelerating in tandem. Key themes include legacy infrastructure undermining AI initiatives, skepticism over AI's return on investment, geopolitical and regulatory uncertainty reshaping strategy, distrust of how companies explain workforce decisions, and rising personal risk for technology leaders. “AI adoption is moving quickly, but our research shows that enterprises are increasingly recognizing the importance of the foundation underneath it. For many organizations, legacy infrastructure is be
Kyowa Kirin and Knight Therapeutics Enter Into Exclusive Distribution Agreement for POTELIGEO ® (mogamulizumab) for Cutaneous T-Cell Lymphoma (CTCL) Patients Across Latin America29.9.2026 15:00:00 EEST | Press release
Kyowa Kirin International, a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), today announced the signing of an exclusive distribution agreement with Knight Therapeutics (“Knight”) (TSX: GUD) for the distribution of mogamulizumab in select countries in Latin America. Under the terms of the agreement, Knight will be responsible for seeking the necessary regulatory approvals and commercialising mogamulizumab for mycosis fungoides (MF) and Sézary syndrome (SS), two subtypes of CTCL, a rare non-Hodgkin’s lymphoma, in Argentina, Brazil, Colombia and Mexico. Knight will hold exclusive distribution rights for the medicine in these markets. Kyowa Kirin and Knight’s collaboration aims to support CTCL patients and improve their access to innovative therapies in Latin America. Céline Rhême, Cluster General Manager, Emerging Growth Markets, Kyowa Kirin, commented: “CTCL is more common in this region than many realise, and further work is needed to identify unmet needs and
Heaviside Industries Awarded $99M IDIQ Contract to Provide MOTH Spectrum Analyzers to U.S. Army29.9.2026 15:00:00 EEST | Press release
Heaviside Industries, a builder of multi-domain precision munitions platforms, announced it has been awarded a $99 million firm-fixed-price, indefinite delivery, indefinite quantity (IDIQ) contract by the U.S. Army to deliver its MOTH radio frequency (RF) spectrum analyzers in support of the Army’s electromagnetic spectrum operations (EMSO) priorities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260929455358/en/ The five-year contract was awarded by U.S. Army Contracting Command at Aberdeen Proving Ground, Maryland and includes system procurement, fielding, upgrades, and sustainment. As unmanned systems proliferate and adversaries increasingly exploit the electromagnetic spectrum, the Army requires EMSO capabilities that are scalable, adaptable, and rapidly fieldable to maintain an advantage in the spectrum. Heaviside’s MOTH meets this need with real-time, passive RF detection in a low size, weight, power, and cost system
Royal Yacht International Represents Buyer in Landmark 132M Lürssen as Founder Predicts: “The Billion-dollar Yacht Is Coming”29.9.2026 15:00:00 EEST | Press release
Royal Yacht International has announced PROJECT M, a fully custom 132-metre Lürssensuperyacht exceeding 6,000 GT. But for Royal Yacht International Founder and CEO Tommaso Chiabra, the project is less about size than what it represents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260928365204/en/ Project M At the very top of the luxury market, the world’s most exceptional yachts are becoming increasingly difficult to reproduce. Only a small number of shipyards can execute projects of this scale. Construction takes years. Specialist capacity is finite. Build slots are scarce. And replacement cost can change dramatically between contract signing and delivery. “People look at purchase price. Sophisticated owners look at replacement value. What would somebody have to spend, and how long would they have to wait, to recreate your yacht when it is delivered?” For RYI, this is changing the role of the yacht broker. HUNDREDS OF MI
Create Apps Championship Winners Highlight Dubai’s Strength as a Base for Scaling Digital Businesses29.9.2026 14:49:00 EEST | Press release
Winners of past editions of Dubai Chamber of Digital Economy’s Create Apps Championship have highlighted how Dubai is helping entrepreneurs transform promising ideas into scalable digital ventures, with the championship playing a key role in supporting their growth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260929068961/en/ During Create Apps Championship 2025 (Photo: AETOSWire) Launched in 2023 as part of the ‘Create Apps in Dubai’ initiative, the championship supports participants through specialised training, mentorship, connections with investors and partners, and funding to develop and launch winning apps. Mariam Mohammed Almarri, Co-Founder of Boom, said: “A major milestone in our journey was participating in the Create Apps Championship, where Boom was recognised as ‘Dubai’s App of the Year 2025’ and ‘Most Impactful App’. This recognition enabled us to build Boom and transport it from an idea into a real product.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom